June 21, 2013
Cellnovo, the leading innovator in mobile diabetes management technology, announced today the appointment of
as non-executive director.
Mr. Garibotto is a 20 year veteran of the medical device industry and has been instrumental in the development, formation, and financing of highly successful medical device companies including Insulet Corporation (IPO
, Nasdaq: PODD) and TransVascular, Inc. (acquired by Medtronic in Sept '04). He is presently the founder and Chief Technology Officer of Securus Medical Group, Inc. Mr. Garibotto has earned a B.Sc. in Industrial Technology from the
University of Massachusetts at Lowell
and a Masters in Business Administration from
"It is a real pleasure to welcome John as director," said
, Cellnovo's Executive Chairman. "John has vast experience in complex medical device development. His expertise and guidance will be invaluable as we prepare to submit our mobile-diabetes management system for US approval."
"I'm delighted to join the board of this outstanding company," said
. "Cellnovo has developed a game-changing approach to the treatment and follow up of patients with type 1 diabetes. I am very impressed by the mobile, real-time technology that Cellnovo have used for their system, which will undoubtedly address the many unmet needs of both patient and care teams."
A UK-based medical device company, Cellnovo develops an innovative mobile diabetes management system. Comprised of a mobile connected patch pump, mobile touchscreen handset/controller, blood glucose meter and applications, the Cellnovo system provides intuitive operation, wireless Internet connectivity and real-time tracking, all industry firsts. For further information, please visit